New drug cocktail shows promise for controlling common lymphoma
NCT ID NCT04404088
First seen Apr 19, 2026 · Last updated Apr 25, 2026 · Updated 2 times
Summary
This study tests a combination of three drugs (acalabrutinib, lenalidomide, and rituximab) in 60 people with untreated stage III-IV follicular lymphoma. The goal is to see if the combination can shrink or eliminate tumors and keep the disease under control. Participants must have measurable disease and meet criteria for starting treatment. This is not a cure; the aim is to manage the cancer long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE III GRADE 1 FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.